Noah Raaum


Merck & Co

Merck is a giant pharmaceutical company. You may have seen commercials for Keytruda or Remicade, some of their most popular drugs. Interestingly, they also developed the first mumps, chickenpox, rubella, and hepatitis B vaccines—but those are history. Merck’s value has climbed steadily over the past year, from $50 to $80, and hasn’t even gotten close to its all-time high of $90 in 2000, indicative of stability. Moreover, Merck just acquired Immune Design, a company that is “harnessing the immune system to fight disease,” with promising and novel approaches to vaccinations.

The Rubicon • Copyright 2024 • FLEX WordPress Theme by SNOLog in

Comments (0)

Comments are welcomed on most stories at The Rubicon online. The Rubicon hopes this promotes thoughtful and meaningful discussion. We do not permit or publish libel or defamatory statements; comments that advertise or try to sell to the community; any copyrighted, trademarked or intellectual property of others; the use of profanity. Comments will be moderated, but not edited, and will post after they are approved by the Director of RubicOnline.  It is at the discretion of the staff to close the comments option on stories.
All The Rubicon Picks Reader Picks Sort: Newest

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.